Our Clinical Advisors

Professor Dame Lesley Fallowfield has published over 360 papers and books. She lectures and runs training workshops throughout the world in psychosocial oncology, quality of life assessment and communication skills.

In 2010, she was awarded the Pfizer/BOA Excellence in Oncology Lifetime Achievement Award. Dame Lesley’s research interests include assessment of Patient Reported Outcomes (PROs), supportive interventions for symptoms & side-effects of cancer and its treatment.

She creates innovative training courses and materials to assist healthcare professionals’ communication with patients, their families and clinical colleagues.

Dr. Joseph Kim, a medical oncologist, specializes in the treatment of genitourinary cancers. While at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors.

He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). He is an active member of Society of Immunotherapy of Cancer and ASCO. He is currently on the protocol review board at Yale University.

Dr. Kim has been involved in numerous clinical trials as both the Principal investigator and sub-investigator. He has been invited to speak at both international and national cancer conferences and has authored or co-authored approximately 20 articles, chapters or case studies.

Prof. Gascón holds the position of Director, Division of Medical Oncology and, Scientific Coordinator of the Hematology-Oncology Department, at the Hospital Clinic in Barcelona. He is board-certified in internal medicine and hematology, as well as medical oncology.

From 1985 to 1999, he was the Director of the Division of Hematology-Oncology at UMDNJ-New Jersey Medical School where he graduated with a PhD. He has published more than 200 papers in peer-reviewed journals.

His main clinical interests are in breast and colorectal cancer and in palliative care, in particular bone marrow toxicities.

Professor Karin Jordan is the leading senior physician of the Department of Hematology and Oncology at the University Hospital in Heidelberg, Germany. Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel in 2009 and 2015 as well as a member of the ASCO antiemetic guideline panel.

She is the ESMO Faculty coordinator for Supportive & Palliative Care and the ESMO Clinical Practice Guidelines subject editor for the supportive care section. Professor Jordan has authored and co-authored more than 120 publications.

Her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

Dr. Arvind Dasari, a medical oncologist, treats cancers of the colon, rectum, pancreas, liver and neuroendocrine tumors at MD Anderson Cancer Center. He completed a Fellowship in Human Genetics at the University of Pittsburgh and a Fellowship in Oncology at the University of Colorado.

He is a member of SWOG as well as Co-Chair of the MD Anderson Neuroendocrine Multidisciplinary Conference. He has received multiple honors and awards from associations such as AACR and ASCO. He has authored over 50 publications including articles, abstracts, and book chapters related to cancers of the GI tract. He acts as a reviewer for the Annals of Oncology, the Annals of Surgical Oncology and Neuroendocrinology.

Dr. Dasari speaks internationally at conferences and seminars related to GI Cancers and is a member of associations such as the AMA, ASCO, AACR, NANETS and others.

Dr. Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medicinal approach to a selection of novel therapies as well as understanding biologic mechanisms of drug sensitivity and resistance.

Dr. Yu is involved with a number of national organizations such as ASCO and NCI. He holds positions as a Special Clinical Expert on the Steering Committee for GU Cancers at the NCI and is an Advisory Member on the Board of the Society of Urology Oncology.

Dr. Yu has published over 200 articles, abstracts and posters and has been invited to speak at conferences and workshops internationally.

Dr. Matti Aapro is presently Dean of the Multidisciplinary Oncology Institut at Genolier. He is also a Board Member of ECCO (European CanCer Organisation) and he serves the International Society for Geriatric Oncology (SIOG) as Executive Board Member.

He is past-President of the Multinational Association for Supportive Care in Cancer (MASCC). He is a member of the ESMO Faculty and chairs the ESMO 2017 Supportive/Palliative Care track.

Dr. Aapro is Editor of Critical Reviews in Oncology/Hematology and the Journal of Geriatric Oncology. He has authored more than 350 publications and his major interests are new drug development, breast cancer, cancer in the elderly, and supportive care.

Dr. Paolo Bossi is a medical oncologist devoted to head and neck cancer treatment. He is particularly dedicated to rare head and neck cancers (paranasal sinus cancer, adnexal cancer, nasopharyngeal cancer, salivary gland cancer).

He is currently evaluating the impact of treatment and treatment-induced toxicities in elderly patients. He is greatly committed to supportive care, and is studying the impact of the microbioma in the development of treatment-related toxicities.

He is also dedicated to non-melanoma skin cancer, with a strong commitment to translational evaluation of the response to new drugs.